
Express Mail No. EL762623628US



27123





**†AFFIX CUSTOMER NO. LABEI** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

# **UTILITY APPLICATION AND FEE TRANSMITTAL §(1.53(b))**

BOX I	issioner for Patents PATENT APPLICATION ngton, D.C. 20231			
Sir:				
Transn	nitted herewith for filing is the patent application of			
Invento	or(s) names and addresses:			
(1)	David Meeker 93 rue Jouffroy Paris 75017 France			
(2)	Seng H. Cheng 50 Wall Street Wellesley, Massachusettes 02481			
	Additional inventors are listed on a separate sheet			
For:	COMBINATION ENZYME REPLACEMENT, GENE THERAPY AND SMALL MOLECULE THERAPY FOR LYSOSOMAL STORAGE DISEASES			
Enclos	ed Are:			
40 1 2 2 6	page(s) of specification page(s) of Abstract page(s) of claims sheets of ⊠ Formal ☐ Informal drawings page(s) of Declaration and Power of Attorney			
	<ul> <li>☑ Unsigned</li> <li>☐ Newly Executed</li> <li>☐ Copy from prior application</li> <li>☐ Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)</li> </ul>			

630103 v1

	Information Disclosure Statement
	Copy of [] cited references  PTO Form-1449
	References cited in parent application Serial No, filed
	Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)
	A copy of related pending U.S. Application(s) Serial No(s):, filed, respectively, is attached hereto.
	A copy of related pending U.S. Application(s) entitled,, filed to inventor(s), respectively, is attached hereto.
	A copy of each related application(s) was submitted in parent application serial no, filed
	Preliminary Amendment
$\boxtimes$	Return receipt postcard (MPEP 503)
	This is a continuation divisional continuation-in-part of prior application serial no, filed, to which priority under 35 U.S.C. §120 is claimed.
	Cancel in this application original claims of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
	A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).
	The status of the parent application is as follows:
	A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until
	A copy of the Petition for Extension of Time in the co-pending parent application is attached.
	No Petition for Extension of Time and Fee therefor are necessary in the copending parent application.
	Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.
	Transfer the drawing(s) from the parent application to this application
	Amend the specification by inserting before the first line the sentence:  This is a continuation divisional continuation-in-part of co-pending application Serial No, filed

	Number Filed	Number Extra	Rate	Basic Fee \$710.00/355.00
Total Claims	11-20=	0x	\$18.00/ \$9.00	\$ 0
Independent Claims	1- 3 =	0x	\$80.00/ \$40.00	\$ 0
Multiple Depender	nt Claims	If marked, add fee of \$270.00 (\$135.00)		\$ 0
			TOTAL:	\$ 710.00 <sup>~</sup>

	Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith
	\$
	A check in the amount of \$ in payment of the application filing fees is attached.
$\boxtimes$	Charge fee to Deposit Account No. <u>13-4500</u> , Order No. <u>4274-4000</u> . A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
	The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4274-4000. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted, MORGAN & FINNEGAN, L.L.P.

Dated: June 19, 2001

By:

Kenneth H. Sonnenfeld

Registration No. 33,285

## Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone (212) 751-6849 Facsimile

# 

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): DAVID MEEKER, ET AL.

Group Art Unit:

To Be As signed

Serial No.:

To be Assigned

Examiner:

To be Assigned

Filed:

June 19, 2001

For:

COMBINATION ENZYME REPLACEMENT, GENE THERAPY AND SMALL

MOLECULE THERAPY FOR LYSOSOMAL STORAGE DISEASES

## **EXPRESS MAIL CERTIFICATE**

Express Mail Label No.:

El 762623628US

Date of Deposit:

June 19, 2001

I hereby certify that the following attached paper(s) and/or fee

- 1. UTILITY APPLICATION AND FEE TRANSMITTAL §(1.53(B)) (4 pages in duplicate)
- 2. SPECIFICATION (40 pages); ABSTRACT (1 page); CLAIMS (2 pages)
- 3. FORMAL DRAWINGS FIGURES 1A-1B (2 Sheets)
- 4. COMBINED DECLARATION AND POWER OF ATTORNEY (6 pages Unexecuted)
- 5. RETURN RECEIPT POSTCARD

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Kenneth H. Sonnenfeld

(Typed or printed name of person mailing papers(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, NY 10154-0053

(212) 758-4800 Telephone

(212) 751-6849 Facsimile